SMC accepts ferumoxytol (Rienso®) for restricted use in the treatment of iron deficiency anaemia

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has accepted ferumoxytol (Rienso®) for restricted use within NHS Scotland for the intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease. Its use is restricted to non-haemodialysis dependent adult patients with chronic kidney disease when oral iron preparations are ineffective or cannot be used.   The Detailed Advice accompanying the recommendation (see link below) summarises the evidence on efficacy and safety, the clinical effectiveness issues and the health economic evidence considered by the SMC. This notes that in two phase III studies, the mean increase from baseline in haemoglobin was significantly higher for ferumoxytol than oral iron in non-haemodialysis dependent patients with chronic kidney disease. A mixed treatment comparison demonstrated equivalent efficacy outcomes for ferumoxytol versus a range of intravenous iron preparations.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news